Organization | ImCyse

ImCyse Report issue

For profit Phase 2

Founded: Liege Belgium (2010)

Organization Overview

First Clinical Trial

2015

NCT02427776

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Imcyse SA

Active Ingredients

Drugs in Phase 2 Trials (4)

autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

imcy-0098 (3 trials)

imcy-0141 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 4